Tag Archives: MRK

Merck & Company (MRK) Receives a Buy from Credit Suisse

In a report released today, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $95.00. The company’s shares closed last Wednesday at $81.64. Biasio has an average

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (NYSE: MRK), Neurocrine (NASDAQ: NBIX) and Select Medical (NYSE: SEM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merck & Company (MRK – Research Report), Neurocrine (NBIX – Research Report) and Select Medical (SEM – Research Report). Merck & Company (MRK) In a

Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $100.00. The company’s shares closed last Friday at $80.24. According to TipRanks.com, Goldstein

Credit Suisse Maintains Their Buy Rating on Merck & Company (MRK)

In a report released today, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $95.00. The company’s shares closed last Friday at $77.67. According to TipRanks.com, Biasio

Mizuho Securities Remains a Buy on Merck & Company (MRK)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $100.00. The company’s shares closed last Thursday at $75.78. According to TipRanks.com, Goldstein ‘s ranking currently

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), PerkinElmer (NYSE: PKI) and Nevro Crop (NYSE: NVRO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK – Research Report), PerkinElmer (PKI – Research Report) and Nevro Crop (NVRO – Research Report). Merck & Company (MRK)